CEL-SCI To Commence Phase III Trial Of Multikine In Bosnia And Herzegovina

(RTTNews) - CEL-SCI Corp. (CVM) announced it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine. The company plans to enroll approximately 30 patients in Bosnia and Herzegovina through three clinical centers.

The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant, 10% improvement in overall survival of enrolled patients who are treated with Multikine plus Standard of Care, or SOC, vs. subjects who are treated with SOC only.